CD47 and primary cutaneous T-cell non-Hodgkin lymphoma: Cutaneous T-cell lymphoma (CTCL) is not an exception; moreover, significant overexpression of CD47 in Sézary syndrome [14] and mycosis fungoides [15] makes CTLC an ideal candidate for anti-CD47 therapy.